25 August 2016 - Mylan doubling the eligibility for patient assistance, effectively eliminating out-of-pocket expense for uninsured and under-insured patients.

Mylan today announced it is taking immediate action to further enhance access to EpiPen (epinephrine injection, USP) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs.

The company is reducing the patient cost of EpiPen Auto-Injector through the use of a savings card which will cover up to $300 for their EpiPen 2-Pak. For patients who were previously paying the full amount of the company's list price for EpiPen, this effectively reduces their out-of-pocket cost exposure by 50%.

Mylan also is doubling the eligibility for its patient assistance program, which will eliminate out-of-pocket costs for uninsured and under-insured patients and families as well.

Read Mylan press release